Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials-Reference-Cited by-同舟云学术

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials

Published:2017-10-06 Issue:1 Volume:32 Page:68-72
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Paul C.¹,Guenther L.²³,Torii H.⁴,Sofen H.⁵^ORCID,Burge R.⁶⁷,Lin C.Y.⁶,Potts Bleakman A.⁶,Mallbris L.⁶,Poulin Y.⁸

Affiliation:

1. Dermatology Department; Toulouse University and Larrey Hospital; Toulouse France

2. Western University; London ON Canada

3. Guenther Research Inc.; London ON Canada

4. Division of Dermatology; Tokyo Yamate Medical Center; Tokyo Japan

5. Department of Medicine (Dermatology); David Geffen School of Medicine; Los Angeles CA USA

6. Eli Lilly and Company; Indianapolis IN USA

7. Division of Pharmaceutical Sciences; University of Cincinnati; Cincinnati OH USA

8. Laval University and Centre de Recherche Dermatologique du Quebec Metropolitain; Quebec City QC Canada

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14581/fullpdf

Reference19 articles.

1. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines;Fitch;Curr Rheumatol Rep,2007

2. Psoriasis: rationale for targeting interleukin-17;Girolomoni;Br J Dermatol,2012

3. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis;Gordon;J Am Acad Dermatol,2014

4. IL-17 targeted therapies for psoriasis;Chiricozzi;Expert Opin Investig Drugs,2013

5. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004;Kurd;J Am Acad Dermatol,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study;Journal of the European Academy of Dermatology and Venereology;2024-06-26

2. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium;Immunotherapy;2023-10

3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12

4. Psoriasis with facial skin lesions that arose against background of withdrawal of ixekizumab (clinical case);Medical alphabet;2023-05-01

5. Modeling Posttreatment Prognosis of Skin Lesions in Patients With Psoriasis in China;JAMA Network Open;2023-04-06